medcom24 - Das Presseportal für Medizin & Gesundheit im Internet.

Deutschlands Datenbank für Presseinformationen aus dem Gesundheitswesen.

Benutzeranmeldung

Bleiben Sie mit - medcom24 - immer auf dem Laufenden!

Kooperationen / Partner

RSS - Newsfeed

Inhalt abgleichen

Feed anzeigen und abonnieren• Sitemap anzeigen

    Presseportal Kostenlos Online PR RSS News Public Relations Veröffentlichen Web 2.0 Gesundheit Journalisten Presse Redaktionen Healthcare Medizin Pressemeldungen PKs Kommunikation Pressekonferenzen Termine Kostenfrei PI Presseinformationen Werbung Öffentlichkeitsarbeit Pressemitteilungen VAs Marketing PR-Agenturen Veranstaltungen


      Mitglied im Deutschen Journalisten-Verband


      Geprüft auf Sicherheit durch:
      Web-Browser optimiert.

    Innovative diagnostics enables improved individual treatment of colon cancer

    On the 1st of October, GeneWake started a project funded by the Federal Ministry of Education and Research (BMBF) to improve diagnostics of colorectal cancer.
    Modern cancer therapy is focusing increasingly on a more personalized treatment of the individual patient. This is due to the fact that even tumors of the same type differ from one another in their molecular properties, which leads to a quite different patient`s response to a given cancer therapy. In colorectal cancer some genes – so called biomarkers – are often particularly affected by changes. These mutations can, for example, result in resistance to usual therapeutic agents. To reach the best possible treatment for each patient, the molecular analysis of these biomarkers will become increasingly important.
    Dr. Robert Loewe, the CEO of GeneWake explains the innovation character of this project: ” Due to the financial assistance of BMBF, GeneWake will develop a new diagnostic test for colorectal cancer. This test enables the physician to examine a tumor tissue section both for changes in cell morphology and for the presence of mutations in the most therapeutically relevant biomarkers KRAS, BRAF and PIK3CA. The result provides accurate information about the extent and the distribution and location of the given changes in the tumor.”
    With more than 70,000 yearly incidences, colon cancer is the second most frequent cancer in Germany. Dr. Sabine Ott, Head of Business Development at GeneWake, states: „The objective of this innovative test is to spare patients ineffective treatments and in many cases to support the doctor in finding an effective and targeted therapy. At the same time, GeneWake contributes to the realization of an affordable personalized treatment of colorectal cancer.”
    The project “Innovative histological detection of mutations in KRAS, BRAF and PIK3CA for personalized treatment of colorectal cancer” runs for three years and is supported by the Federal Ministry of Education and Research (BMBF) with around 450,000 Euro.

    Contact
    Dr. Sabine Ott
    GeneWake GmbH
    Floriansbogen 2-4
    82061 Neuried
    info@genewake.com
    www.genewake.com

    Presseportal - medcom24 e.K. | Copyright 2008 - 2018 | All rights reserved | SERVICE-HOTLINE: 01801 / 730 730 | Powered by Drupal Design by Artinet